Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8386 to 8400 of 8905 results

  1. Apremilast for treating active psoriatic arthritis (TA372)

    This guidance has been updated and replaced by NICE technology appraisal guidance 433.

    Withdrawn guidance

  2. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)

    This guidance has been updated and replaced by NICE technology appraisal guidance 412.

    Withdrawn guidance

  3. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10. 

    Withdrawn guidance

  4. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338)

    This guidance has been updated and replaced by NICE technology appraisal guidance 427.

    Withdrawn guidance

  5. Hearing disability - hearing aids (TA8)

    This guidance has been withdrawn.

    Withdrawn guidance

  6. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.

    Withdrawn guidance

  7. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1038.

    Withdrawn guidance

  8. Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)

    NICE has withdrawn this guidance. Novartis will stop marketing crizanlizumab (Adakveo) because its marketing authorisation has been withdrawn by the Medicines and Healthcare products Regulatory Agency (MHRA). Novartis has issued a direct letter to healthcare professionals specialising in haematology. No new people will start taking crizanlizumab in the UK. Healthcare professionals should discuss alternative treatment options with people currently having crizanlizumab.

    Withdrawn guidance

  9. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1018.

    Withdrawn guidance

  10. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA759)

    This guidance has been updated and replaced by NICE technology appraisal guidance 835.

    Withdrawn guidance

  11. Newer drugs for epilepsy in adults (TA76)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guidance

  12. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1042

    Withdrawn guidance

  13. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1043.

    Withdrawn guidance

  14. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1040.

    Withdrawn guidance

  15. Dapagliflozin for treating chronic kidney disease (TA775)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1075.

    Withdrawn guidance